Matteo Tardelli, Francesca V. Bruschi, Claudia D. Fuchs, Thierry Claudel, Nicole Auer, Victoria Kunczer, Maximilian Baumgartner, Onne A.H.O. Ronda, Henk Jan Verkade, Tatjana Stojakovic, Hubert Scharnagl, Aida Habib, Robert Zimmermann, Sophie Lotersztajn, Michael Trauner – 10 September 2019
Tirthadipa Pradhan‐Sundd, Karis Kosar, Harvinder Saggi, Rong Zhang, Ravi Vats, Pamela Cornuet, Sydney Green, Sucha Singh, Gang Zeng, Prithu Sundd, Kari Nejak‐Bowen – 6 September 2019
Elliot B. Tapper, James B. Henderson, Neehar D. Parikh, George N. Ioannou, Anna S. Lok – 6 September 2019 – Hepatic encephalopathy (HE) is a devastating complication of cirrhosis. Data are limited regarding the incidence of and risk factors for HE among contemporary patients in the context of the shifting epidemiology of cirrhosis. We examined a 20% random sample of U.S. Medicare enrollees with cirrhosis and Part D prescription coverage from 2008 to 2014. We modelled incident HE using demographic, clinical, and pharmacologic data.
Brian P. Lee, Norah A. Terrault – 5 September 2019
Kathy M. Nilles, Stephen H. Caldwell, Steven L. Flamm – 4 September 2019 – Thrombocytopenia is common in patients with advanced liver disease. These patients frequently require invasive diagnostic or therapeutic procedures in the setting of thrombocytopenia. A common platelet goal before such procedures is ≥50,000/μL, but target levels vary by provider and the procedure. Platelet transfusion has disadvantages, including safety and cost.
Adrien Guillot, Frank Tacke – 4 September 2019
Zongyi Yang, Jia Feng, Li Xiao, Xi Chen, Yuanfei Yao, Yiqun Li, Yu Tang, Shuai Zhang, Min Lu, Yu Qian, Hongjin Wu, Ming Shi – 3 September 2019
3 September 2019
Vijay Prabhakar, Paul Y. Kwo – 3 September 2019